This guideline provides recommendations for diagnostic and therapeutic procedures for patients with malignant gliomas. We diff erentiate evidence-based standards from reasonable options or non-evidence-based measures that should no longer be considered. The recommendations herein should provide a framework and assurance for the choice of diagnostic procedures and therapeutic measures and aim to reduce complications from unnecessary treatment and cost. The guideline contributes to a critical appreciation of concurrent drugs with a focus on the controlled use of anticonvulsants and steroids. It should serve as a guideline for all professionals involved in the diagnostics and care of glioma patients and also as a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in Europe. Implementation of the recommendations summarised here will need interdisciplinary structures of care for patients with brain tumours and structured processes of diagnostic and therapeutic procedures.
Introduction
This guideline for the diagnosis and treatment of gliomas follows the Third Revision of the WHO Classifi cation of Tumours of the Central Nervous System. 1 It covers WHO grade III anaplastic astrocytomas, oligodendrogliomas, and oligoastrocytomas; WHO grade IV glioblastomas (including its variants) and gliomatosis cerebri; and WHO grade III and IV gliomas of brainstem and spinal cord. The guideline covers prevention, early diagnosis and screening, therapy, follow-up, and rehabilitation for patients with malignant gliomas. It does not cover diff erential diagnoses of gliomas and adverse eff ects of therapeutic measures in depth. The structure of the guideline was based on the national guideline on gliomas of the German Society of Neurology and the German Cancer Society.
The guideline aims to serve medical professionals of all disciplines involved in the diagnosis and care of patients with glioma, particularly neurologists, neurosurgeons, radiation oncologists, neuropathologists, neuro radiologists, oncologists, paediatric oncologists, epileptologists, psycho-oncologists, rehabilitation specialists, palliative care nursing specialists, and neuro-oncology nursing specialists. Furthermore, the recommendations could serve as a valuable source of information for patients, relatives, other health professionals, and health insurance companies.
General recommendations
Recommendations for the general approach to patients with malignant gliomas, including diagnostic aspectsie, early diagnosis and prevention, history, clinical examination, neuroimaging, cerebrospinal-fl uid analyses, electroencephalography, preoperative management, biopsy and resection, histological classifi cation and grading, molecular diagnostics-and general recommendations for therapy (eg, surgical therapy, radiotherapy, pharmacotherapy, and other therapeutic approaches) are summarised in the appendix.
Specifi c recommendations Anaplastic astrocytoma-WHO grade III
Anaplastic astrocytomas have inhomogeneous density on CT scans and appear as hyperintense, space-occupying lesions on T 2 -weighted fl uid-attenuated inversion recovery (FLAIR) MRI. They tend to show patchy enhancement after contrast administration and often have peritumoural oedema. However, a substantial proportion (up to 30%) of these tumours can show no enhancement on CT or MRI. Abnormal vessels can be visualised by MRI angiography. Favourable prognostic factors include young age, high Karnofsky performance score, IDH1/2 mutation, and MGMT promoter methylation. 2 Furthermore, loss of ATRX expression may defi ne a subgroup of anaplastic astrocytic tumours with a more favourable prognosis. 3 The traditional standard of care for anaplastic astrocytoma includes maximum resection as feasible or biopsy, followed by involved-fi eld radiotherapy to 60 Gy given in 1·8-2 Gy fractions (table 1) . 4 Findings from randomised trials 5, 6 using radiotherapy after resection or biopsy showed a doubling of median survival time compared with surgery alone. Findings from a meta-analysis 7 suggested effi cacy for adjuvant chemotherapy using nitrosourea compounds as a part of fi rst-line treatment; the proportion of patients who survived for 1 year increased from 58% to 63%, and for 2 years increased from 31% to 37%. However, metaanalyses are potentially biased because trials with negative fi ndings are less likely to be published than trials with positive fi ndings. The addition of PCV (procarbazine, lomustine, and vincristine) chemotherapy to radiotherapy had no survival benefi t for the subgroup of patients with anaplastic glioma in a large Medical Research Council (MRC) trial. 8 Conversely, fi ndings from the German Neuro-Oncology Group (NOA)-04 trial 9 showed that alkylating chemotherapy alone (eg, PCV or temozolomide) was as eff ective as was radiotherapy alone in terms of progression-free survival, with similar overall survival in both groups, but at the time of publication, there was insuffi cient follow-up to draw meaningful conclusions for the overall survival data, particularly for the patients with good prognosis.
A retrospective analysis 10 of the NOA-04, NOA-08, and German Glioma Network studies suggested that IDH1/2 mutation status could serve as a predictive biomarker of benefi t from the addition of temozolomide to radiotherapy; patients with IDH1/2 wildtype tumours with a methylated MGMT promoter might benefi t from the inclusion of alkylating chemotherapy in fi rst-line treatment.
The present standard of care outside clinical trials, based on NOA-04, 9 remains radiotherapy or alkylating chemotherapy alone for patients with anaplastic astrocytoma (which typically lacks 1p/19q co-deletion). Temozolomide is often preferred to PCV because of its favourable safety and tolerability profi le. The CATNON trial (European Organisation for Research and Treatment of Cancer [EORTC] 26053, NCT00626990) is examining the addition of temozolomide to fi rst-line radiotherapy, as concomitant or adjuvant temozolomide, or both, for patients with tumours without the 1p/19q co-deletion, most of which are anaplastic astrocytomas. Long-term results from NOA-04 and data from CATNON should direct whether the standard of care for these patients should be modifi ed.
At progression, the option of second surgery should be explored. Initial therapy generally establishes the therapeutic options at recurrence. Alkylating chemotherapy is the treatment of choice for most patients previously untreated with chemotherapy who progress after radiotherapy. Temozolomide and nitrosoureas are probably equally eff ective. A median progression-free survival of 23 weeks and 46% of patients remaining progression-free at 6 months in a phase 2 trial led to the approval of temozolomide in this indication; 11 14 of 111 patients in the study had anaplastic oligoastrocytoma. A similar study of temozolomide and a variant of the standard PCV regimen used widely in Europe (table 2) showed similar effi cacy. 12 Bevacizumab is often used after failure of radiotherapy and alkylating chemotherapy, dependent on local availability, with 20-60% of patients remaining progression free at 6 months. [13] [14] [15] However, controlled trials have not been done, and no evidence supports the combination of bevacizumab with cytotoxic drugs for these patients.
For recurrent patients who have already had radiation, hypofractionated radiotherapy (eg, with 25-30 Gy in fi ve fractions of 5 or 6 Gy, or with 35 Gy in ten 3·5 Gy fractions) is feasible if recurrences are circumscribed and chemotherapy is contraindicated. Further irradiation should be given as fractionated stereotactic radiotherapy, conformal radiotherapy with tight margins, or image guided radiotherapy. However, the size and patterns of recurrent tumours often preclude reirradiation, and the overall effi cacy is disputed.
Anaplastic oligodendroglioma and oligoastrocytoma-WHO grade III
The defi nition of anaplastic oligoastrocytoma remains a matter of debate and has been challenged because of poor inter-observer agreement and incomplete molecular defi nition. Extent of resection is a prognostic factor in these tumours, too. 9, 16 In the NOA-04 trial, 9 in which histological diagnoses were verifi ed by central neuropathology review at study entry, anaplastic oligodendroglioma and mixed anaplastic oligoastrocytoma had similar clinical courses, which were more favourable than that of anaplastic astrocytoma. In the next revision of the WHO classifi cation, molecular markers should be integrated to refi ne the present morphology based classifi cation for anaplastic gliomas. 2, 3 Among anaplastic gliomas, there is high correlation between oligodendroglial morphology and 1p/19q co-deletion. Tumours with 1p/19q co-deletion almost always have IDH1/2 mutations, and often have MGMT promoter methylation and TERT promoter mutations. 17 By contrast, TP53 mutation and loss of ATRX expression are rare in 1p/19q-co-deleted gliomas, but common in diff use and anaplastic astrocytomas. This fi nding could help to better dissect the controversial entity of anaplastic oligoastrocytoma. 3 See Online for appendix
Newly diagnosed Progression
Anaplastic astrocytoma, WHO grade III Resection or biopsy followed by radiotherapy or chemotherapy (or combined modality treatment) Resection or biopsy, followed by radiotherapy, or temozolomide with or without radiotherapy based on MGMT and performance status
Resection and chemotherapy or radiotherapy that explored the value of PCV polychemotherapy, either before or immediately after radiotherapy, suggest that the inclusion of chemotherapy in fi rst-line treatment confers a survival advantage which becomes evident only after follow-up of more than 6 years and only in the subgroup of patients with 1p/19q-co-deleted tumours. Thus, 1p/19q co-deletions have also predictive value for benefi t from chemotherapy, in addition to the characterisation of a prognostically more favourable subgroup of patients with anaplastic oligodendroglial tumours. Although these results mostly stem from retrospective analyses of small patient cohorts and are thus explorative, both studies show very similar results in the patients with 1p/19q-co-deleted tumours. Important questions remain, however; for example, how many of the long-term survivors treated with radiotherapy plus PCV experienced preserved cognitive function and quality of life? Could the same improvement in overall survival have been achieved with the combination of radiotherapy and temozolomide or even with alkylating chemotherapy alone? Long-term results from the NOA-04 trial, 9 which compared radiotherapy versus temozolomide versus PCV alone, might shed light on some of these questions. At present, phase 3 clinical trials in patients with 1p/19q-co-deleted oligodendroglial tumours should include radiotherapy plus PCV as a standard group. In clinical practice, many sites have reverted to classic radiotherapy plus PCV as a standard of care, whereas other clinicians prefer temozolomide concurrent with radiotherapy, followed by adjuvant temozolomide or even temozolomide alone, particularly in young patients (table 2, appendix). Accordingly, the amended three-group CODEL trial (NCT00887146) will compare radiotherapy followed by PCV with temozolomide concurrent with radiotherapy followed by adjuvant temozolomide with temozolomide alone.
Treatment following progression is aff ected by type of and response to fi rst-line treatment as outlined for anaplastic astrocytoma. If neither radiotherapy nor alkylating chemotherapy are options because they failed or because of intolerance, bevacizumab can be considered as a salvage strategy, depending on local availability. 13, 15, 22, 23 Proper controlled studies are lacking here, however, and there is also no evidence to combine bevacizumab with cytotoxic drugs for these patients.
Glioblastoma-WHO grade IV
Glioblastomas appear as space-occupying lesions on MRI or CT with irregular boundaries and often enhance after administration of contrast agents. Central necrosis and perilesional oedema are common. Angiography shows highly abnormal vasculature with arteriovenous shunting and early venous drainage. Interestingly, in the growing population of elderly patients with malignant gliomas, there is no major diff erence in prognosis between anaplastic astrocytoma and glioblastoma. [24] [25] [26] Surgery is a key element within the management, either as diagnostic biopsy or as a microsurgical resection. However, class I evidence for the value of microsurgical resection is still lacking. In a small randomised trial 27 in Finland, patients with glioblastoma or anaplastic astrocytoma older than 65 years had a median survival of 171 days after resection compared with 85 days after biopsy (p=0·035). 27 This study has been criticised because of small patient numbers (30 enrolled, 13 patients biopsied vs 10 patients resected) and major imbalances in Karnofsky performance scores between groups. Although some recent clinical series have reported gradually extended survival associated with extent of resection, investigators of other studies proposed that only a gross total resection is associated with better outcome. 28 Meanwhile many tools are available to increase the extent of resection while keeping the risk of new neurological defi cits low. These include the routine use of surgical navigation systems housing functional MRI datasets when available, intraoperative MRI, and intraoperative functional monitoring. The fl uorescent dye 5-aminolevulinic acid (ALA) helps to visualise glioblastoma tissue during microsurgical tumour resection. Its use was associated with an increased rate of gross total resections and an increased progression-free survival rate at 6 months. 29 Whether its use prolongs survival remains unknown; 30 moreover, the pivotal study was performed before temozolomide concurrent with radiotherapy followed by adjuvant temozolomide became standard of care.
Radiotherapy has been standard of care for glioblastoma for decades, with an undisputed major survival benefi t. 4 The radiotherapy volume often includes the T 1 -enhanced region plus a 2-3 cm safety margin on the T 2 or FLAIR abnormality. 4 The standard dose is 54-60 Gy given in 1·8-2 Gy fractions. A regimen of 50 Gy in 1·8 Gy fractions was better than best supportive care in patients aged 70 years or older. 31 Patients with adverse prognostic factors defi ned by age or performance status or both are now often treated with hypofractionated radiotherapy (eg, 40 Gy in 15 fractions). 32 In elderly patients, this regimen is now preferred for patients with tumours lacking MGMT promoter methylation. 26, 33 Neither accelerated hyperfractionated nor hypofractionated regimens nor brachytherapy nor radiosurgery or a stereotactic radiotherapy boost have been shown to be superior to standard fractionation in terms of survival. 4 A meta-analysis found the combination of nitrosourea-based chemotherapy with radiotherapy in newly diagnosed glioblastoma increased the proportion of Review patients achieving 1-year survival from 31% to 37% and 2-year survival from 9% to 13%. 7 No diff erences between single nitrosourea compounds or between mono therapy and nitrosourea-based combination therapies were identifi ed. The MRC trial comparing radiotherapy alone with radiotherapy plus PCV showed no increase of survival with the addition of chemotherapy. 8 Local 1,3-bis(2-chlorethyl)-1-nitrosourea (BCNU) wafer chemotherapy added to radiotherapy conferred survival of 13·9 months compared with 11·6 months for radiotherapy alone for the intention-to-treat population, but the diff erence was no longer signifi cant when patients with anaplastic gliomas were removed from the cohorts. [34] [35] [36] Its effi cacy and safety in combination with temozolomide concurrent with radiotherapy followed by adjuvant temozolomide have not been adequately explored.
Concomitant and adjuvant temozolomide chemotherapy plus radiotherapy is now the standard of care for adult patients with newly diagnosed glioblastoma aged up to 70 years and in good general and neurological condition. 37, 38 The benefi t from temozolomide is most prominent in patients with glioblastoma with MGMT promoter methylation. 39, 40 Temozolomide is given at 75 mg/m² during radiotherapy and for six maintenance cycles on 5 out of 28 days at 150-200 mg/m² thereafter. There is no benefi t from increasing the dose of temozolomide in the setting of newly diagnosed disease 41 and extending the duration of chemotherapy beyond six cycles is also not supported by clinical trial data. For individual patients, increasing the number of adjuvant temozolomide cycles may be considered-eg, for patients with stable or incompletely regressing, residual, contrast-enhancing tumours at completion of six cycles of temozolomide.
Findings from two randomised trials in adults with glioblastoma have shown a gain in progression-free survival of 3-4 months, but not overall survival, when patients with newly diagnosed glioblastoma received bevacizumab in addition to temozolomide and radiotherapy followed by temozolomide. 42, 43 Interpretation of the data from these trials remains controversial. 44 For the increasing population of elderly patients with glioblastoma, new standards of care were defi ned in 2012. On the basis of fi ndings from the NOA-08 and Nordic trials, 26, 33 MGMT testing should be standard practice. 45 Patients with tumours lacking MGMT promoter methylation should receive hypofractionated radiotherapy alone, which is also the preferred treatment for patients with tumours with unknown MGMT status. Those with tumours with MGMT-promoter methylation should be treated with temozolomide alone (treatment for 5 of every 28 days until progression or for 12 months) or with temozolomide and radiotherapy followed by temozolomide. The role of early radiotherapy in addition to temozolomide in these patients will be better understood when data from the ongoing EORTC and National Cancer Institute of Canada (NCIC) Clinical Trial Group elderly trial (NCT00482677) can be compared with those of the NOA-08 and Nordic trials.
Best supportive care can be the preferred option in patients with large or multifocal lesions with Karnofsky performance scores of less than 50, particularly in patients who cannot provide informed consent for further therapy beyond biopsy.
Standards of care for patients with recurrent glioblastoma are not well defi ned and clinical decision making is often based on previous treatment, age, Karnofsky performance score, and patterns of relapse. About 20-30% of patients with recurrent glioblastoma are candidates for second surgery, which should typically be considered when patients have large but circumscribed lesions causing neurological defi cits and when the interval between surgeries is more than 6 months. However, surgery for progressive glioblastoma can also be considered earlier in symptomatic patients, especially in patients with suboptimum initial surgery. The role of reirradiation is uncertain, including the role of aminoacid PET for target delineation, and multiple fractionation regimens have been proposed-eg, from six doses of 5 Gy to 18 doses of 2 Gy. 46, 47 The three strategies of medical treatment for glioblastoma recurring after temozolomide with concurrent radiotherapy followed by temozolomide most often used across Europe include nitrosourea-based regimens, alternative dosing regimens of temozolomide, and bevacizumab. The activity of lomustine has been confi rmed in the standard groups of randomised trials exploring the activity of the protein kinase C-β inhibitor, enzastaurin, 48 or the VEGF receptor inhibitor, cediranib, 49 with progression-free survival at 6 months of 20%. Somewhat better control at 6 months has been reported with a continuous dosing regimen of temozolomide, 50 but not in a recent phase 2 trial exploring a 21 out of 28 days schedule. 51 The BR12 trial, 12 which enrolled recurrent, temozolomide-naive patients with malignant glioma provided no evidence for superiority of dose-intensifi ed temozolomide over standard-dosed temozolomide, but these data are of limited value in assessment of the role of temozolomide rechallenge for patients pre-exposed to temozolomide. They do, however, suggest that there is no rationale for use of dose-intensifi ed temozolomide in patients with recurrent glioma who are temozolomide-naive.
Although bevacizumab has been approved for the treatment of recurrent glioblastoma in several countries, it has not been approved in the European Union on the basis of fi ndings from two prospective (but uncontrolled) phase 2 trials that showed radiological response rates of 30% or more and progression-free and overall survival times interpreted to be better than those of historical controls. 52, 53 The value of bevacizumab in the management of progressive malignant gliomas in clinical practice is almost universally accepted because of evident (albeit transient) symptom relief and steroid-sparing eff ects. However, timing and dosing schedules remain www.thelancet.com/oncology Vol 15 August 2014 e399 Review controversial, and an eff ect on overall survival has not been shown. No active combination partner for bevacizumab has been identifi ed in the setting of progressive disease, albeit in uncontrolled or noncomparative trials, suggesting that bevacizumab monotherapy should be given outside clinical trials. Preliminary data indicate that the combination of bevacizumab and lomustine might be better than either drug alone, 54 suggesting that this combination warrants further exploration as planned in a phase 3 trial by the EORTC.
Gliomatosis cerebri
The diagnosis of gliomatosis cerebri is based on the histological verifi cation of a glioma and needs radiological demonstration of diff use signal changes suggestive of a tumour aff ecting at least three cerebral lobes. The diagnosis is thus not based on histology alone. Typically, the tumour aff ects both cerebral hemispheres and can extend into the basal ganglia and brainstem. Gliomatosis cerebri can correspond to WHO grades II, III, or IV, based on histological fi ndings in the respective biopsy specimens, but resembles diff use (WHO grade II) astrocytomas in most patients. The diagnostic concept of gliomatosis cerebri has proven diffi cult to use in clinical practice and trials, and will probably be revised with support of molecular markers and advanced imaging technology. The imaging features are quite characteristic and include a diff use hyperintense tumour on T 2 /FLAIR images involving both the white and grey matter, nonenhancing or with small patchy areas of contrast enhancement. Perfusion MRI and magnetic resonance spectroscopy can be useful to diff erentiate rare non-neoplastic lesions. In selected patients in whom intracranial pressure is substantially high, decompressive craniectomy can ultimately be considered at the time of biopsy to prevent rapid neurological deterioration. The clinical course of gliomatosis cerebri is highly variable, but occasionally younger patients can be followed up for years without specifi c therapy. IDH1/2 mutations are associated with improved outcomes. Surgery is often restricted to a diagnostic biopsy. Radiotherapy and alkylating chemotherapy are active treatments. The role of radiotherapy as initial treatment is limited because of the high dose needed for control of glioma growth and the large target volumes needed in gliomatosis cerebri. Both PCV and temozolomide are often used as alternatives to radiotherapy. 55, 56 The NOA-05 trial 57 explored the effi cacy of primary chemotherapy with procarbazine and lomustine, omitting vincristine because of poor penetration of the blood-brain barrier; investigators reported treatment failure at 8 months in fewer than half of patients, and a median overall survival of 30 months.
Brainstem gliomas and spinal gliomas
Diff use intrinsic pontine gliomas are a major challenge in paediatric neuro-oncology. Although children are often treated on the basis of neuroimaging alone, histological verifi cation of the diagnosis is usually mandatory in adults, especially in cases of enhancing lesions, because of a higher error rate by imaging alone and a broader range of diff erential diagnoses. 58 Magnetic resonance spectroscopy can aid diff erential diagnosis if biopsy is not feasible or refused by the patient. Anaplastic gliomas and glioblastomas of brainstem and spinal cord are rare and no data from clinical studies are available. Resection is restricted to exophytic tumours because of the expected neurological defi cits with surgery in the brainstem and spinal cord. Radiotherapy is the standard of care, and temozolomide or nitrosoureas or bevacizumab can be used in the course of disease following the considerations for supratentorial tumours of the same WHO grades.
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Monitoring and follow-up
Whenever feasible, MRI should be used to monitor the effi cacy of pharmacotherapy or as surveillance imaging after completion of treatment. 60 Intervals of 3 months are recommended for most patients with malignant gliomas, although longer intervals might be considered for patients with lengthy disease control, notably young patients with 1p/19q-co-deleted oligodendroglial tumours.
Supportive care and patient management Raised intracranial pressure
Raised intracranial pressure due to growth of a glioma is an emergency situation that needs immediate intervention, often with high doses of steroids and occasionally with osmotic agents. Acute surgical decompression is rarely needed. Whether de compressive surgical interventions make sense in the further course of disease, once the diagnosis has already been established and primary therapy given, needs consideration of the options for further treatment after the surgical intervention.
Thromboembolic events
Patients with glioma are at increased risk of thromboembolic events throughout the course of disease for many reasons, including motor defi cits, steroid drugs, radiotherapy, chemotherapy, immobility, and release of vasoactive molecules from glioma cells. 61 The importance of this comorbidity increases with the use of antiangiogenic drugs as therapeutics against gliomas because these drugs are also associated with the risk of ischaemic and haemorrhagic vascular events. Although anticoagulation using coumadin derivatives is feasible in patients with glioma, low-molecular-weight heparins are often preferred due to a favourable safety profi le. 61 A single study 62 about primary prophylaxis using such drugs was prematurely stopped, but provided no evidence for a decreased incidence of fi rst thromboembolic events. Vena cava fi lters might be an option for patients who cannot be anticoagulated.
Review Epilepsy
Patients with glioma who never suff ered symptomatic seizures should not receive primary prophylaxis with anti convulsant drugs. 63 A single seizure usually necessitates anticonvulsant drug treatment until the under lying tumour growth is controlled by tumourspecifi c therapy. 64 If no further seizure occurs after surgery and the tumour seems to be controlled by treatment, tapering of anticonvulsants should be attempted within the fi rst weeks or months after surgery and further tumour-specifi c therapy. Recurrent seizures after surgery usually indicate lifelong need for anticonvulsants. The choice of drug for patients requiring secondary prophylaxis is guided by various considerations. 65, 66 The classic drugs include carbamazepine, valproic acid, and phenytoin and are of similar effi cacy. All anticonvulsants are associated with relevant toxicities in brain tumour patients. Phenytoin and carbamazepine share an unfavourable side-eff ect profi le, including drug interactions, and are therefore not suited for long-term therapy of patients with brain tumours. Moreover, carbamazepine is not available intravenously and often induces vertigo and nausea after initial dosing, particularly in elderly patients. Long-term use impairs cognitive function. The enzyme-inducing properties of phenytoin, carbamazepine, and barbiturates can decrease the activity of many chemotherapeutic drugs, whereas the enzyme-inhibitory properties of valproic acid might accentuate toxic eff ects from, and possibly activity of, chemotherapy; for example, patients given valproic acid had improved outcomes, but also increased haematological toxic eff ects, in the experimental group of the EORTC NCIC temozolomide trial. 67 Drugs such as levetiracetam, gabapentin, lamotrigine, or topiramate off er advantages compared with the classic drugs, mainly because of lack of drug interactions. In particular, levetiracetam is often preferred because of good tolerability, rapid dosing, and intravenous availability. Lamotrigine is an attractive alternative if slow dosing is an option. Lacosamide and perampanel are new drugs that need investigation in patients with brain tumours. Clonazepam and other benzodiazepines should only be used transiently (eg, during dosing of lamotrigine). This guideline does not address the competence to drive with a brain tumour, because driving capabilities are subject to country-specifi c regulations which are beyond the scope of this guideline.
Steroids
Steroids are often prescribed to patients for control of tumour-associated oedema. The need to continue steroid treatment in patients with brain tumours should be reviewed at each visit because of the major burden of side-eff ects, with eff ects on quality of life and the potential interference with tumour-specifi c therapies. Drug interactions, increased risk of infection and thrombosis, myopathy, and depression are only a few of the frequently reported side-eff ects. The option to taper steroids rapidly after tumour debulking should not be missed. Patients who have undergone substantial resection often tolerate radiotherapy with no steroids, or a small dose in the fi rst week. Patients who have undergone biopsy might only need steroids at the start of radiotherapy, but moderate doses (4-8 mg daily) will suffi ce, and can often be tailed off during or soon after treatment. Bevacizumab is a powerful steroid-sparing drug, but should not be used solely for this purpose. Other approaches to replace steroids as anti-oedema drugs in neuro-oncology are being explored.
Psychological and social support
Psychological stress and the social eff ects of the disease on patients and their families and caregivers should not be underestimated. Psychiatric comorbidity should be actively explored and treated accordingly, with both psychotherapy and pharmacotherapy. 68 Recognition of the social eff ects of having a brain tumour and adequate counselling in such circumstances are an integral aspect of care for patients. The eff ects of therapy in this patient population with reduced life span also need to be considered. 69 Diverse support can be benefi cial from individuals such as nurse specialists in neuro-oncology, social workers, counsellors, clinical psychologists, palliative-medicine professionals, and patient focus groups.
Rehabilitation
The need for rehabilitative measures should be explored during and after tumour-specifi c therapy. Type and intensity of these measures depend not only on cognitive and neurological function, but also on age and expected course of disease. Inpatient and outpatient rehabilitation are options. Amelioration of neurological and neuropsychological defi cits are the main goals of neurological rehabilitation in brain tumour patients. Coping strategies for living with a malignancy are the main goal for rehabilitation with a psychological focus. 70 
Palliative care
The appropriate timepoint and setting for communication with patients about the foreseeable restrictions and limitations of tumour-specifi c measures needs to be carefully assessed, and not done too late in the course of the disease. During advanced stages of disease, specifi c antineoplastic treatments might not be warranted, and palliative care becomes very important. Patients need specialised nurses, social workers, and coordinated care at home or in another adequate setting. Review can become necessary. In the terminal stage, analgesics and sedatives should be provided in suffi cient doses. Support to fi nd the best individual setting of dying should be off ered and a strategy for the last phase of the illness discussed together with patients and caregivers at an appropriate stage.
Coordination of care
Clinical decision making for patients with malignant gliomas should ideally be based on recommendations from interdisciplinary tumour boards from the fi rst diagnostic and therapeutic decisions onwards. Such boards could also be the ideal forum for discussion of which parts of the treatment plan can be achieved locally, which parts need a specialised centre, which measures need inpatient or outpatient settings, and what intensity of neurorehabilitative measures is in the patient's interest. Local and national guidelines could serve for orientation beyond this guideline.
Conclusions
Guidelines refl ect the state of knowledge at a given timepoint. Table 3 summarises the key recommendations of the EANO task force in 2013. The EANO website will inform of future updates on this guideline.
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Class of evidence 72
Level of recommendation 72 
General recommendations
Karnofsky performance score, neurological function, age, and individual risks and benefi ts need to be considered in clinical decision making in neuro-oncology 
Glioblastoma (WHO grade IV)
Standard of care for glioblastoma (age <65-70 years) includes resection as feasible or biopsy, followed by involved-fi eld radiotherapy and concomitant and adjuvant (six cycles) temozolomide chemotherapy 37 I A Elderly patients who are not candidates for temozolomide concurrent with radiotherapy followed by adjuvant temozolomide should be treated with radiotherapy (eg, 15 doses of 2·66 Gy) alone or temozolomide (5/28) based on MGMT promoter methylation status, on the basis of the fi ndings of the NOA-08 and Nordic trials 26, 33 I A At recurrence, standards of care are less well defi ned; nitrosourea regimens, temozolomide rechallenge, and (with consideration of the country-specifi c label) bevacizumab are options for pharmacotherapy; when available, recruitment into appropriate clinical trials should be considered
II B
PCV=procarbazine, lomustine, and vincristine.
Table 3: Key recommendations
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